Towards a Green Pharmaceutical Future in Europe
Authors/Creators
-
Ferrer Pérez, Pablo
(Editor)1
-
Fernández Ruiz, Carlos
(Editor)1
-
Ilgrande, Chiara
(Editor)1
- Pérez Genovés, Lucía (Editor)1
- Hernández Pedraza, Diego (Editor)2
-
Silva, Patrícia
(Editor)3
-
Harrison, Sam
(Editor)4
-
Camarinopoulos, Stephanos
(Editor)5
-
Giakoumaki, Aggeliki
(Editor)5
-
Antonaropoulos, George
(Editor)6
-
Harasek, Michael
(Editor)7
-
Stevens, Christian V.
(Editor)8
-
De Coensel, Nathalie
(Editor)9
-
Kümmerer, Klaus10
-
Moermond, Caroline
(Editor)11
-
Leonardo Alves, Teresa
(Editor)11
-
Ragas, Ad
(Editor)12
-
Luisi, Renzo
(Editor)13
-
Oliveira, Mariana
(Editor)14
-
Vilé, Gianvito
(Editor)15
-
Benyahia, Brahim
(Editor)16
-
Sáenz de la Torre Lasierra, Juan José
(Editor)17
-
Flamarique Pérez, Leyre
(Editor)17
- Fernández García, Jesús Ignacio (Editor)18
-
Colacino, Evelina
(Editor)19, 20
-
1.
Asociacion de Investigacion de Materiales Plasticos y Conexas
- 2. ASPHALION
- 3. Center for Mechanical Technology and Automation (TEMA) / University of Aveiro
- 4. UK Centre for Ecology & Hydrology
-
5.
RISA Sicherheitsanalysen
- 6. IRES - Innovation in Research and Engineering Solutions
-
7.
TU Wien
- 8. Ghent Unversity
-
9.
Ghent University
-
10.
Leuphana University of Lüneburg
-
11.
National Institute for Public Health and the Environment
-
12.
Radboud University Nijmegen
-
13.
University of Bari Aldo Moro
-
14.
University of Aveiro
- 15. Politecnico di Milano
-
16.
Loughborough University
- 17. Agata Communications
-
18.
Agata Communications (Spain)
- 19. Université de Montpellier
-
20.
Institut Charles Gerhardt Montpellier
Description
Pharmaceutical products are essential to public health, but their life cycle—from research and development, to synthesis, process development use and disposal—can carry high environmental costs. Traditional manufacturing often relies on hazardous solvents, energy-intensive processes, and long, linear supplychains. Meanwhile, after use, active pharmaceutical ingredients (APIs) and their metabolites can persist in the environment, contributing to pollution and risks to ecosystems.
Addressing these challenges requires a systemic life cycle approach that integrates environmental sustainability into pharmaceutical research and development, production, use, and disposal. Recognizing these challenges, the European Commission has launched an ambitious Green Pharma agenda, funding five Horizon Europe projects—
ENVIROMED, ETERNAL, IMPACTIVE, SusPharma and TransPharm—that together form an informal Green Pharma Cluster. Their collective insights provide strong evidence base for policy action.
Files
Informal Green Pharma Cluster - Policy Brief - Towards a Green Pharmaceutical Future in Europe.pdf
Files
(8.3 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:ff6db1b4ea1ea63990c0542c11e1e45e
|
8.3 MB | Preview Download |
Additional details
Funding
- European Commission
- ETERNAL - Boosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle. 101057668
- European Commission
- ENVIROMED - Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact 101057844
- European Commission
- TransPharm - Transforming into a sustainable European pharmaceutical sector 101057816
- European Commission
- SusPharma - MERGING SUSTAINABLE AND DIGITAL CHEMICAL TECHNOLOGIES FOR THE DEVELOPMENT OF GREENER-BY-DESIGN PHARMACEUTICALS 101057430
- European Commission
- IMPACTIVE - Innovative Mechanochemical Processes to synthesize green ACTIVE pharmaceutical ingredients. 101057286